Cost-effectiveness of zoledronic acid (ZOL) versus denosumab (Dmab) in prevention of skeletal-related events (SREs) in castration-resistant prostate cancer metastatic to the bone (mCRPC).
S. J. Snedecor
Consultant or Advisory Role - Novartis
J. A. Carter
Consultant or Advisory Role - Pharmerit
S. Kaura
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
M. Botteman
Consultant or Advisory Role - Pharmerit